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Delayed cerebral vasospasm has classically been considered the most important and treatable cause of mortality and morbidity
in patients with aneurysmal subarachnoid hemorrhage (aSAH). Secondary ischemia (or delayed ischemic neurological deficit,
DIND) has been shown to be the leading determinant of poor clinical outcome in patients with aSAH surviving the early phase and
cerebral vasospasm has been attributed to being primarily responsible. Recently, various clinical trials aimed at treating vasospasm
have produced disappointing results. DIND seems to have a multifactorial etiology and vasospasm may simply represent one
contributing factor and not the major determinant. Increasing evidence shows that a series of early secondary cerebral insults
may occur following aneurysm rupture (the so-called early brain injury). This further aggravates the initial insult and actually
determines the functional outcome. A better understanding of these mechanisms and their prevention in the very early phase is
needed to improve the prognosis.The aim of this review is to summarize the existing literature on this topic and so to illustrate how
the presence of cerebral vasospasm may not necessarily be a prerequisite for DIND development. The various factors determining
DIND that worsen functional outcome and prognosis are then discussed.
1. Introduction
SAH accounts for only 5% of all strokes, with an incidence
of nine per 100,000 person years [1]. Half the patients are
younger than 55 years and therefore SAH has a severe
economic and social impact [2]. One in six patients die
during the sudden onset of bleeding and those who survive
may die or deteriorate owing to early aneurysmal rebleeding,
secondary delayed cerebral ischemia (DCI), hydrocephalus,
or medical complications. Approximately 70% of patients die
or subsequently need help with the ordinary activities of daily
life [3].
Secondary DCI occurs in c. 30% of all patients [4] and
results in poor outcome in half of these [3]. The high risk
period for DIND is between 4 and 10 days after aneurysm
rupture [4]; the pathogenesis is still incompletely understood,
but classically it has been attributed to cerebral vasospasm
[5].
During the last century there was a wide consensus
that cerebral vasospasm was the most important determi-
nant of poor prognosis in patients with aSAH [6]. Re-
search was mainly directed to control and prevent delayed
vasospasm, often with disappointing results. Indeed radio-
logical improvement of vasospasm does not correlate clearly
with changes in functional outcome [7, 8]. Over the last
decade, growing experimental and clinical evidence has
demonstrated that the presence of delayed vasospasm of the
major cerebral vesselsmay indeed be a contributing factor but
not necessarily the principal determinant of DCI and DIND.
Indeed, cerebral infarction can also occur when vasospasm
is not angiographically detected in the territorial artery [9]
and poor outcome in aSAH seems to be directly dependent
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on infarction but independent of vasospasm [10]. There is
increasing evidence that other coexisting factors may be
involved in the development of DIND and their character-
isation and treatment could improve the consistently poor
clinical outcome in patients with aSAH.
The aim of this review is to discuss the various mech-
anisms contributing to the poor prognosis in patients with
SAH and to redefine the role of delayed cerebral vasospasm
in DIND.
2. Early Brain Injury
The term early brain injury (EBI) was first coined in 2004
to explain the acute pathophysiological events occurring
within 72 hours of aSAH that begin minutes after bleeding
commences [11, 12].These events include cerebral autoregula-
tion and blood-brain barrier (BBB) disruption, activation of
inflammatory pathways, excitotoxicity, oxidative stress, and
activation of apoptosis [13]. These are direct effects of the
presence of blood in the subarachnoid space and also of
transient cerebral ischemia. Brain injury is not limited to
the primary site of haemorrhage; many of the mechanisms
occurring with EBI contribute to the pathogenesis of delayed
ischemic injury and are thus responsible for subsequent
poor outcome. Hence early detection of EBI may make
it possible to predict patient outcome; logically, therefore,
early intervention that inhibits such changes may decrease
mortality and improve overall outcome.
2.1. Mechanical Injury and Cerebral Autoregulation Disrup-
tion. Immediately after an aSAH a reactive constriction of
the artery supplying the ruptured aneurysm occurs, thus
producing a mechanical injury [14]. The consequence is an
acute global ischemia leading to BBB disruption through
endothelial cell death [15, 16]. Furthermore, both vasogenic
and cytotoxic brain oedema may contribute by elevating
intracranial pressure (ICP) and impairing cerebral blood flow
(CBF).
Early elevation of ICP values is common after SAH. Two
patterns of ICP elevation, namely, transitory and sustained,
are described. The extent of rise in ICP is often used to
predict outcome in SAH [17] and sustained ICP elevation is
associated with higher mortality [18]. This phenomenon is
associated with a severe reduction in CBF, cerebral perfusion
pressure (CPP), and impaired cerebral autoregulation [19,
20], thus increasing mortality rates. Bederson et al. observed
that CBF reduction to less than 40% of baseline in the first
hour after SAHpredicted 100%mortality, independent of ICP
and CPP values [11].
2.2. Electrolyte Disturbances. Electrolyte disturbances are
often observed within the first hours after SAH and they may
be responsible for several mechanisms of EBI. Hyponatremia
develops within 1-2 days from the initial bleed [21] and it
occurs in 10%–30% of patients at admission; it is caused by a
cerebral salt-wasting syndrome and inappropriate secretion
of antidiuretic hormone. The treatment of hyponatremia is
not easy and clinical signs may mimic DIND. Furthermore
hyponatremic patients have a risk of developing delayed
ischemic injury three times higher than normonatremic
patients [22]. Risk factors for hyponatremia include a history
of diabetes, chronic heart, hepatic failure, adrenal insuffi-
ciency, and NSAIDs or diuretic use [23].
Cellular calcium homeostasis is impaired in neuronal,
cerebral endothelial, and smooth muscle cells; the intra-
cellular elevation is due to N-methyl-D-aspartate (NMDA)
glutamate receptor activation and deregulation of adenosine
triphosphatase (ATPase) dependent channels. Pathological
rise in intracellular calcium may result in persistent contrac-
tion of smooth muscle cells in cerebral arteries, also causing
glutamate release and activation of apoptotic pathways [24]
(Figure 1).
Approximately 40% of patients admitted within 48 hours
after SAH have abnormally low serum magnesium [25].
Magnesium decrease contributes to the rise in intracellular
calcium by blocking NMDA receptors in an activated state
and this provokes vasoconstriction, platelet aggregation,
release of excitatory aminoacids, and increased synthesis of
endothelin-1 (ET-1) [26].
A high level of serum potassium has been detected
after SAH [27], probably owing to decreased activity in
the potassium-sodium pump mechanism. Subarachnoid
haemoglobin combined with a high concentration of potas-
sium may cause widespread constriction of cerebral arteries
and a pathological decrease in CBF.
2.3. Excitotoxicity. The increased interstitial glutamate con-
centration after SAH is linked to cellular leakage, altered
synaptic transmission, BBB disruption, and decreased glu-
tamate uptake [28]. In animal experiments an excitotoxicity
from excessive activation of ionotropic and metabotropic
glutamate NMDA receptors [29] was observed, leading
to excessive intracellular calcium influx and activation of
apoptotic pathways [30]. The NMDA receptor-antagonist,
felbamate, improved neurological performance in ratmodels,
limiting BBB disruption [31] and development of delayed
vasospasm [32]. Similarly blood glutamate scavengers have
been shown to improve neurological outcome in animal
models, but the blockade of NMDA receptors may actually
hinder neuronal survival [33]. In clinical studies glutamate
elevation in cerebral interstitial fluid detected with micro-
dialysis was predictive of ischemia [34] and the release of
excitatory amino acid after SAH measured in interstitial
and cerebrospinal fluid (CSF) correlated strongly with ICP
elevation, secondary brain injury, and poor outcome [35].
2.4. Nitric Oxide Alterations and Endothelin-1 Increase. Alter-
ations in nitric oxide (NO) pathways are described in the
early period after aSAH both in animals and humans. [36,
37] NO is produced by nitric oxide synthase (NOS) which
can be distinguished between endothelial (eNOS), neuronal
(nNOS), and inducible NOS (iNOS). NO plays an important
role in regulating vascular hemodynamic activity; it dilates
vessels by blocking intracellular calcium release from the
sarcoplasmic reticulum in smoothmuscle cells and it inhibits
platelet aggregation and leucocyte adhesion to the endothelial


















layer. Its alteration may disrupt autoregulation homeostasis
and may be related to the pathogenesis of delayed vasospasm
[37]. Animal studies demonstrate that cerebral NO level
decreases within 10min of aSAH [36] and it increases
excessively after 24 hours [38]. The decreased availability of
NOmay be attributed to nNOS destruction and inhibition of
eNOS through the presence of subarachnoid haemoglobin. A
downregulation of eNOS and loss of nNOS in spastic arteries
after SAH have indeed been demonstrated [39].
In clinical studies, increased cerebral NO levels are found
24 hours after aSAH and this indicates a poor prognosis
[37, 40]. Inflammation activates iNOS and NO production
may act as a vasodilator, in the form of peroxynitrite or as
free radical itself, causing an oxidative stress in the vascular
wall at the critical moment [41].
Endothelin-1 (ET-1) is the most potent endogenous acti-
vator of vasoconstriction, through the activation of calcium-
dependent and independent mechanisms. The level of ET-1
increases in serumand plasmawithinminutes after SAHwith
a peak 3-4 days after injury [42]; it is physiologically produced
by the endothelium, but in SAH there is an excessive release
by astrocytes during the period of initial ischemia [43].
An upregulation of its receptors is equally observed in
the delayed phase; ETA receptor in particular is expressed
predominantly on smooth muscle cells and is crucial in
vasoconstriction and cell proliferation. ET-1 can produce
long lasting vasoconstriction directly [44] and can induce
morphological changes such as fibrosis or hyperplasia in the
vascular wall [45]. Furthermore, a disequilibrium between
NO and ET-1 level leads to unopposed vasoconstriction and
promotes vasospasm development [46].
2.5. Oxidative Stress. Reactive oxygen species (ROS), prin-
cipally oxygen free radicals, and reactive nitrogen species
(RNS) are both linked to a number of vascular disease states.
Oxidative stress plays a significant role in EBI. Animal and
human studies indicate that ROS are generated early after
SAH resulting in haemoglobin autooxidation and lipid per-
oxidation and a consequent rapid consumption of enzymatic
and nonenzymatic antioxidant defence systems [47]. Such
oxidative stressmay be the trigger for a number of deleterious
pathophysiological changes including structural alterations
in endothelial cells, endothelial dysfunction and proliferation
of smooth muscle cells [48], disruption of BBB, activation
of the inflammatory cascade, and production of powerful
local vasoconstrictors (e.g., leukotrieneC4 and prostaglandin
D2). [47]. The vasodilator effect of bradykinin in cerebral
vessels through an inhibition by ROS further supports such
a hypothesis [49]. The treatment of oxidative stress during
the short effective therapeutic window that exists is difficult;
injury caused by free radicals may well occur before a patient
can receive effective treatment [50].
2.6. Inflammatory Pathways. The correlation between
inflammation and the presence of blood in the subarachnoid
space was established over fifty years ago. In 1955 Walton
demonstrated that febrile patients with SAH have a worse
final outcome than afebrile patients [51]. SAH triggers an
inflammatory cascade: a systemic leucocytosis is commonly
observed [52] and white cells can directly promote free
radical formation, release cytokines and chemotactic factors
to propagate the immunological response, and produce
ET-1 and leukotrienes [53] and consume NO. Furthermore
Spallone et al. have shown how leucocyte concentrations
are more elevated in the CSF of patients with SAH-related
ischemia when compared to controls [52]. By analogy
elevated serum C-reactive protein levels on admission are
known to be related to poor prognosis and the occurrence of
delayed vasospasm [54].
Subarachnoid blood is a stimulant for nuclear fac-
tor 𝜅-light-chain-enhancer of activated B cells (NF-𝜅B),
which mediates the transcription of multiple components
of the inflammatory cascade, including adhesion molecules,
cytokines, and complement [55].
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Tumor necrosis factor-alpha (TNF𝛼) may also have a
critical role in determining EBI. According to Starke et
al., TNF𝛼 contributes to the formation and rupture of the
aneurysm and inhibitors of TNF𝛼may therefore be beneficial
not only in preventing aneurysmal progression and rupture
[56], but also in limiting the inflammatory process after
subarachnoid bleeding.
Cytokines and chemokines may be implicated in the
development and maintenance of neurovascular injury with
an early increase at six hours and a late peak between 48 and
72 hours. Their elevation in serum, CSF, and microdialysis
fluid is related to early and delayed ischemia and poor
outcome [44, 57].
In particular, as shown by Muroi et al., higher serum
interleukin-6 (IL-6) levels are associated with worse clinical
outcome and DIND. Thus it is feasible that IL-6 levels may
also be used as a marker to monitor clinical progression [58].
The serum and CSF levels of endothelial adhesion
molecules (in particular E-selectin, ICAM, and VCAM-1),
which are vital to the capture, rolling, transmigration, and
diapedesis of leucocytes to the site of inflammation, are
significantly elevated after aSAH [59]. Their increase within
the first three days of haemorrhage is associated with poor
outcome [60].
A quantitative correlation between the degree of inflam-
matory response and the prognosis in patients with SAHmay
therefore be possible.
2.7. Blood Breakdown Products. Haemoglobin may cause
vasoconstriction by direct oxidative stress (as oxy-Hb or
as bilirubin oxidation products (BOXes)) [61] and also by
altering the balance between NO and ET-1. Oxy-Hb is a
strong spasmogenic substance; it causes prolonged contrac-
tion of smooth muscle cells when applied to cerebral arteries
in vivo and antagonists seem to prevent the occurrence of
vasospasm [62]. It can catalyse the generation of superoxide
and hydrogen peroxide, resulting in subsequent lipid per-
oxidation. Furthermore haemoglobin may scavenge nitric
oxide, destroy nNOS, and alter eNOS functionality and itmay
indeed stimulate ET-1 production [63].
Bilirubin formation is maximal during the third or fourth
day after SAH and BOXes reach a maximal concentration
during the major vasospasm period (4–11 days). However,
BOXes seem to be potentiators rather than initiators of
vasospasm [64].
The role of iron in early brain injury after SAH was
investigated by Lee et al. [65]; they showed how iron chelator
desferroxamine halved mortality, attenuated DNA damage,
and lessened induction of iron-handling proteins in exper-
imental models [66]. Treatment was efficacious as early as
the first day and by improving all outcomes significantly,
supporting the contention that toxic blood metabolites are
significant in early brain injury [66]. Both ferrous and ferric
iron are prooxidant molecules and ROS may promote the
transcription of NF-𝜅B and activator protein-1 [67], thus
activating inflammatory pathways. ROSproduction catalyzed
by free iron may also cause vasogenic oedema and increase
ICP by disrupting BBB [68].
2.8. Small Vessel Spasm. Vascular spasm on angiographic
imaging is restricted mostly to proximal large vessels and it
occurs 3–7 days after SAH. However evidence from exper-
imental studies shows that the constriction effect seen on
parenchymal small vessels within the first minutes after SAH
is greater than on large proximal vessels [11, 69]. Technical
reasons limit the data on SAH-induced microcirculatory
changes to animal studies. They demonstrate the presence of
abnormal pial microcirculation with spasm of the microvas-
culatures, decreased blood flow and agglutination of red
blood cells [70]. In the majority of patients, aSAH induces
multiple vasospasm of arterioles without angiographic signs
of vasospasm or increases in blood flow on evaluation with
transcranial Doppler.
Uhl et al. confirmed constriction of small vessels in
patients undergoing surgery within the first 72 h after aSAH
[71] and they proposed that SAH is associated with a
microvascular spasm primarily involving arterioles, with
constriction in pial vessels and decrease in capillary den-
sity. Pennings later confirmed this finding [72]. In animal
and postmortem pathological studies a disruption of the
basal membrane and the endothelial layer was demonstrated
[73], with morphological changes being more evident on
parenchymal vessels compared to large vessels [74]. These
may contribute to early clinical signs and may influence
the postoperative course [71]. In particular endothelial dys-
function is considered to be one of the key factors initi-
ating early vasoconstriction, keeping in with a decreased
response to vasodilators (such as acethilcoline, bradikinine,
or thrombin) which require a functional endothelium [75].
Basement membrane degradation seems to be more related
to destabilization ofmicrocirculation and increase in vascular
permeability and interstitial oedema [76]. Whether these
early changes in microcirculation can be used as a prognostic
factor for the development of delayed proximal vasospasm
remain to be proven.
2.9. Cortical Spreading Depolarization. Cortical spreading
depolarization (CSD) is a wave of almost complete depo-
larization of the neuronal and glial cells that occurs in
different neurological diseases [77]. It is observed within the
first 72 hours of SAH and it occurs probably as a result of
the irritating activity of subarachnoid haemoglobin and an
elevated extracellular potassium, glutamate, and ET-1 [78].
This results in a breakdown of ion gradients characterized
by a change in the negative potential with an amplitude
between−10 and−30mV and a duration of about oneminute.
The histological result is neuronal oedema and dendritic
distortion. The combination of decreased CBF and increased
energy requirements imposed by CSD may worsen neuronal
injury [79]. Clustered spreading depolarisations are related to
metabolic changes suggestive of ongoing secondary damage
primarily in nonischemic brain tissue [80]. Experimentally,
spreading depolarization leads to massive increase in gluta-
mate, decrease in glucose, and increase in lactate levels [81].
Under pathologic states of hypoperfusion, cortical spreading
depolarizationmay produce oxidative stress, worsen hypoxia,
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Figure 2
and induce neuronal death [16]. Elevated intracellular cal-
cium is possibly the predominant mediator of neuronal
death from ischemia [82] (Figure 2). Clinical studies confirm
how the number of spreading depolarisations recorded with
a subdural electrode strip correlates significantly with the
development of DCI and showed it to be a more reliable
marker than vasospasm seen on angiograms [83, 84].
2.10. Cell Death. Secondary brain injury in particular is
mediated by apoptosis, while a minor role is exercised by
necrosis and autophagy. Cell death starts within 24 hours of
SAH, secondary to an early decrease in CPP and CBF with
the consequent activation of hypoxia-induced factors and
cysteine-aspartic proteases (caspases) [85].
Serum levels of neuron specific enolase, a marker of
neuronal injury, show a trend related to the amount of
subarachnoid blood, which correlates with poor neurological
status on admission [86]. Apoptosis is triggered by elevated
ICP, ischemia, reperfusion, and acute vasospasm and by the
neurotoxicity of blood breakdown components and oxidative
stress [11, 44]. It involves neuronal, glial [87], and smooth
muscle and endothelial cells, causing BBB disruption [88]
and promoting vasospasm development. A pathological ele-
vation of intracellular calcium activates caspase-dependent
apoptotic pathways [89] and beneficial effects have been
observed upon inhibition of caspase activity [90] in terms
of improvement of cerebral vasospasm in animal models
[91]. Furthermore after an interaction between apoptosis and
autophagy was demonstrated, rapamycin and simvastatin
were shown to inhibit apoptosis by activating post-SAH
autophagy [92].
3. Delayed Brain Injury
Many patients survive EBI but deteriorate a few days later
after the hemorrhagic onset. The term delayed brain injury
(DBI) describes critical events arising in the late phase of
aSAH (3–14 days) resulting from the interaction of multiple
pathological pathways as a direct consequence of EBI and
leading to delayed cerebral ischemia (DCI) [93]. DCI causes
poor outcome or death in up to 30% of patients who survive
the initial impact of SAH after having their aneurysm treated
effectively [94]. DCI is actually thought to be caused by the
combined effects of delayed vasospasm, arteriolar constric-
tion, thrombosis and dysfunction in microcirculation, and
cortical spreading ischemia, all processes triggered by EBI.
3.1. Delayed Cerebral Vasospasm. Historically delayed spasm
in cerebral proximal vessels was thought to be the principal
factor responsible for tissue infarction and clinical deterio-
ration and its monitoring was considered a reliable marker
in the followup of aSAH patients. Several studies found
a correlation between radiologically confirmed vasospasm
and clinical symptoms of DCI [95]. In the acute phase it is
considered the result of a prolonged contraction of smooth
muscle cells, with an abnormal endothelial hypertrophy
arising from inflammatory changes and gene expression
modification [96]. An increase in inflammatory cells in the
adventitia is observed with a necrosis in the muscular layer.
In the chronic phase, a proliferation of smoothmuscle cells is
characteristic, probablymediated by ET-1 [97], finally leading
to cerebral ischemia. Vasospasm begins on the third day
after the onset of SAH with a peak at 6–8 days, eventually
lasting 2-3weeks [98]. Clinical predictors are volume, density,
and prolonged presence of SAH (Fisher classification) [99]
and the incidence increases with age and cigarette smoking,
preexisting hypertension, and hypovolemia.
A significant relationship between severity of vasospasm
and the proportion of patients with infarction was shown
by Crowley et al. [100] analyzing the CONSCIOUS-1 data;
a strong association was demonstrated between vasospasm
seen on angiograms and new cerebral infarctions [101].
Thephysiopathology of delayed cerebral vasospasm is still
poorly understood but many mechanisms are shared with
EBI, with activation of inflammatory pathways, oxidative
stress, electrolyte changes, and apoptosis activation playing
an important role. Vasospasm may critically in fact be a late
sign of EBI [102] (Figure 3).
3.2. Microcirculation Dysfunction and Vasospasm. Micro-
circulatory dysfunction is a process distinct from proxi-
mal vessel spasm. Normally autoregulation compensates for
decreased CPP with a proportional vasodilatation [103].
SAH causes failure of the microcirculation, decrease in
the mass density of capillaries and spasm, vasoconstriction,
and pathologic changes in small vessels that may lead to
infarction. Arteriolar diameter is physiologically the primary
determinant for CBF andDIND is likely to be strongly related
to microcirculatory changes [9].
Furthermore after aSAH, the coagulation cascade is
strongly activated with a diffuse formation of microthrombi.
The concentrations of fibrinopeptide A, tissue factor, and
thrombin-antithrombin complexes are significantly elevated
in patients who developed DCI [104]. The pathological
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formation of microthrombi blocking the possibility of col-
lateral revascularisaton or causing a persistent “no-reflow”
phenomenon may represent an alternative explanation for
CBF reduction and DIND, independent of CPP alteration
[74].
Using the index of brain tissue oxygen pressure reactivity
(ORx, a variable correlation coefficient between cerebral
perfusion pressure and partial pressure of brain tissue oxy-
gen), Jaeger et al. showed how impaired autoregulation was
associated with an unfavourable outcome in patients with
SAH, measured according to their Glasgow Coma Score
[105]. Disrupted autoregulation may predict which patients
will finally develop delayed infarction [106].
3.3. Cortical Spreading Ischemia. Cortical spreading ischemia
is a direct consequence of neuronal/glial depolarization
(cerebral spreading depolarization), normally occurring 72
hours after initial haemorrhage. The direct consequence of
CSD is consumption of ATP stores, electrolyte imbalance,
cerebral oedema, and neuronal death, as a result of a
prolonged disproportion between increased metabolic needs
and decreased CBF, thus ultimately producing widespread
cortical necrosis [107].
4. Therapeutic Strategies
Therapeutic strategies in aSAH are currently designed to
treat vasospasm with the ultimate goal of preventing delayed
ischemic injury and improving clinical outcome.
4.1. Triple-H Therapy. Triple-H therapy (hypertension, hy-
pervolemia, and hemodilution) was routinely used for pro-
phylaxis and treatment of cerebral vasospasm.Hyperdynamic
therapy by increasing blood pressure and, if necessary, car-
diac output is considered the best available medical option
for treatment of cerebral vasospasm [108, 109]. Raabe et al.
showed how moderate perfusion pressure, with a CPP of
80–120mmHg in a normovolemic hemodiluted patient, is
an effective method of improving cerebral autoregulation
and is associated with a lower complication rate compared
with hypervolemia or aggressive hypertension therapy [110].
Similarly, Muench et al. showed in experimental models
how triple-H therapy failed to improve regional blood flow
more than maintaining hypertension alone. They showed
that the triple-H therapy was characterized by a detrimental
effect of hypervolemia and/or hemodilution which reversed
the positive effect of induced hypertension on brain tissue
oxygenation [111]. In conclusion, hypervolemia and hemod-
ilution are not beneficial on CBF and are not recommended
nowadays [112].
4.2. Calcium Channel Blockers. Current SAH treatment pro-
tocols include, besides neurointensive care and hyperdy-
namic therapy, the prophylactic administration of nimodip-
ine. The rationale for the use of calcium antagonists for
prevention of secondary ischemia was initially based on
the blocking of the dihydropyridine-type calcium channel,
thereby preventing the influx of calcium into the vascu-
lar smooth-muscle cells and decreasing the rate of cere-
bral vasospasm [113]. After their introduction into clinical
practice it was discovered that calcium-channel blockers
have neuroprotective properties and they seem to provide
beneficial effects without angiographic evidence of cerebral
vasodilatation [113]. Nimodipine, an L-type Ca channel
blocker, is currently the only pharmacologic agent showing
an improvement in neurological outcome when used for
a period of 21 days after aneurysmal rupture. This occurs
without a real effect on cerebral vasospasm [114]. Calcium
blockers seem useful therapeutic agents outside of any effect
on vasospasm [114].
4.3. Magnesium Sulphate. Magnesium sulphate acts as a
noncompetitive antagonist of voltage-dependent calcium
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channels and as a NMDA-receptor antagonist and has
neuroprotective and vasodilator properties [26]. Further-
more magnesium therapy seems to reduce the inflammatory
burden in treated patients [115]. Intravenous magnesium
sulphate was shown by van den Bergh et al. to reduce
cerebral vasospasm and infarct volume after experimental
SAH [25]. However, MacDonald et al. [116] and Veyna et
al. [117] failed to show prevention or clinical improvement
in cerebral vasospasm with magnesium therapy. It has been
considered a promising agent [114] but clinical trials failed
to demonstrate a clear benefit [118]. Nonetheless, the risk of
adverse effects is minimal and some practitioners prefer to
maintain high serum levels of magnesium in patients with
aSAH.
4.4. ET-1 Receptor Antagonists. Disappointing results were
observed in two randomized double blind phase II and
III trials using an ET-1 receptor antagonist (clazosentan)
[119, 120]: ET-1 seems to have a key role in vasospasm but
inhibition of its action seems to reduce cerebral vasospasm
without improving final functional outcome or mortality
[8]. Only a small reduction was observed in the number of
patients exhibiting DIND and there was no beneficial effect
on the Glasgow Outcome Scale (GOS) at 3 months’ followup.
However the sample size estimates for CONSCIOUS-1 trial
were not intended to demonstrate an effect on functional
outcome and the study was underpowered to detect changes
in mortality [119].
The CONSCIOUS-2 trial was designed to investigate
whether clazosentan reduced vasospasm-related morbidity
and all-cause mortality. It however showed no clinical benefit
(including functional outcome) and systemic complications
were more frequent in patients treated with this drug [120].
4.5. Vasodilators. Among vasodilator agents, milrinone has
the added effect of being an inotrope. It is a phosphodiesterase
III inhibitor that increases the level of cyclic adenosine
monophosphate (cAMP); it was first used in the short-term
therapy for chronic heart failure and its first use in the
treatment of cerebral vasospasm after rupture of an intracra-
nial aneurysm was reported in 2001 [121]. Furthermore it
has a supposed anti-inflammatory effect [122]. However, in
order to obtain a direct effect on EBI, vasodilators should be
introduced immediately on hospital admission.
Recent attention was drawn to the vasodilator effects
of oestrogen therapy. Ding et al. showed recently how
17 beta-estradiol (E2) is a potent vasodilator [123]. They
demonstrated in vivo an attenuated cerebral vasospasm on
angiography, which is probably related to a decreased iNOS
expression, a normal eNOS expression, and diminished
ET-1 production [124]. Furthermore, E2 may have direct
antioxidant effects by scavenging ROS and it may decrease
TNF𝛼 expression through a reduction of JNK signalling
activity [125] and of inflammatory pathways. E2 may also
inhibit apoptosis by neuroglobin and ERK pathway activa-
tion. However, it must be noted that known adverse effects
of oestrogen treatment are not negligible.
4.6. Nitric Oxide Donors. NO donors were investigated in
experimental studies (sodium nitrate, sodium nitroprusside,
and nitrite) and they seem to prevent cerebral vasospasm in
a primate model [126]. However, the clinical utility of NO is
limited by its short half-life and its potential toxicity [127].
4.7. Antioxidants. Antioxidants such as methylprednisolone
(also an anti-inflammatory agent) and tirilazad mesylate (a
free radical scavenger) may prevent oxidative stress and EBI
damage [128], though apparently with limited efficacy related
to a one-year functional outcome [50, 129, 130]. Furthermore,
free radical scavengers seem to be associated with a lower
incidence of delayed ischemic injury [131].
Recently Zhang et al. [132] published a study of the use
of astaxanthin (ATX), one of the most common carotenoids
with potent antioxidant properties, on experimental SAH.
The authors showed how ATX (by intracerebroventricular
injection or oral administration) could significantly alleviate
EBI in rat models by reducing brain oedema, BBB disruption,
neural cells apoptosis, and neurological dysfunction. ATX
may have pleiotropic effects through inhibition of glutamate
release [133] by blocking inflammatory pathways (NF-𝜅B)
[134], by limiting apoptosis and by platelets aggregation [135].
No side effects were reported following ATX use [136] and it
may represent a new promising therapeutic option.
4.8. Nonsteroidal Anti-Inflammatory Agents. Different anti-
inflammatory treatments have been studied in cerebral
vasospasmwith contrasting results.This may be explained by
the heterogeneity of inflammatory patterns activated during
aSAH [53]. Currently anti-inflammatory agents are not used
as standard treatment in patients with SAH. However the
use of nonsteroidal anti-inflammatory drugs may produce a
reduction in the inflammatory response and reduce the odds
for unfavourable outcomes [137].
4.9. Antiplatelet Agents and Inhibitors ofThrombus Formation.
Clinical studies using antiplatelet agents show contrasting
outcomes; one study showed a reduced risk of cerebral infarc-
tion in patients using aspirin [138] and another study showed
an increased haemorrhagic volume in patients habitually
using cyclooxygenase inhibitors [139].
Cerebrovascular microthrombosis was also the target of
therapeutic research; ADAMTS-13 inhibits physiologically
thrombus formation and thus inflammatory responses. Its
systemic administration in experimental models diminished
the microthrombotic process and improved neurological
performances probably by limiting neuronal inflammation,
without effects on vasospasm [140].
4.10. Statins. The debate is open for the use of statins as a
therapeutic option in the acute period after SAH. Statins are
hydroxymethylglutaryl- (HMG-) CoA reductase inhibitors
with pleiotropic effects; they may decrease the inflamma-
tory burden und upregulate the production of vasodilator
substances (NO) by modulating eNOS expression [141, 142].
Furthermore statins may reduce the excitotoxicity of glu-
tamate, inhibit platelet aggregation, and prevent apoptosis
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[143]. Some studies showed a decreased incidence of cerebral
vasospasm and of mortality rate in patients treated with
statins [144, 145]. One meta-analysis showed how statin
use decreases the overall incidence of delayed vasospasm,
ischemic injury, and mortality [146], while another meta-
analysis showed no differences in outcome [147].
5. Discussion
Delayed cerebral vasospasm of proximal cerebral vessels has
classically been considered the primary marker to monitor
patients’ progression [148] and the most important and treat-
able cause ofmortality andmorbidity in SAH [149]. In the last
few years, the key role of delayed cerebral vasospasmhas been
questioned; DIND, the principal prognostic determinant in
patients surviving the acute phase, has been shown to be
a multifactorial process. Multiple mechanisms other than
vasospasm may contribute to long-term outcome and the
role of events occurring during the immediate hours after
bleeding has recently been emphasized (Figure 4).
According to the literature, 21% of aSAH survivors, who
do not develop vasospasm, develop delayed ischemic injury
and only 20%–30% of those who develop delayed vasospasm
suffer from delayed ischemic injury [150]. The cerebral blood
flowdiminution observed in patients withmoderate and even
severe vasospasm seems, in fact, not a sufficient cause for
cerebral infarction [9]. Some authors claim that many factors
determine whether infarction develops after vasospasm con-
firmed angiographically, including the duration and severity
of ischemia, the presence and length of stenosis, and the
presence of collateral pathways [151]. In some cases, however,
infarction occurs immediately after SAH without detectable
vasospasm in the territorial artery [152] and other effects such
asmicrothrombus formation or spasm anddysfunction in the
microcirculation may make a significant contribution [153].
Therapeutic strategies in SAH patients are currently
still designed to treat vasospasm with the ultimate goal of
preventing delayed ischemic injury and improving clinical
outcome.These therapies result either in a reduced incidence
of radiologically evident vasospasm without improvement
in delayed ischemic injury or in quality of life (as in the
case of ET-1 receptor antagonists) or in clinical benefit
without evident angiographic response in terms of decreased
vasospasm (as in the case of calcium blockers).
Different reasons may be put forward to explain these
results; bias in the construction of studies could play a role
(e.g., sample populations being not big enough to show a
real clinical benefit or low sensibility of scores chosen to
evaluate clinical outcomes). Furthermore different patholog-
ical pathways may be implicated in the final outcome in
patients suffering from aSAH, independent of any vasospasm
demonstrated angiographically.
The role of vasospasm has probably been misinterpreted;
treating vasospasm alone probably targets the wrong focus
and may not lead to improvement in functional outcome.
The events occurring early after haemorrhage are clearly
responsible for the development of delayed ischemia; the
massive brain damage observed at autopsy in patients dying
within the first 72 hours of haemorrhage confirms the
importance of EBI [154]. Acute intracranial circulatory arrest
[18] promotes metabolic deregulation and impairment of
vascular reactivity resulting in an altered autoregulation and
CO
2
responsiveness [155]. Cortical spreading depolarization,
inflammation, and oxidative stress may contribute further to
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small vessel dysfunction,microthrombosis, and early ischem-
ic signs [156].
Understanding, monitoring, and treating the various
mechanisms at the root of early brain injury will be the key
to improve the prognosis in SAH. Whilst human data are
actually scant, preclinical studies demonstrate that treatment
of EBI improves functional outcome.
Examining what happens early on in aSAH is usually
monitored in the neurological ICU by a multimodal neu-
romonitoring [157]. Data existing strongly suggest that bio-
chemical changes detected with cerebral microdialysis may
precede the onset of secondary neurological deterioration
following SAH [158]. Microdialysis may therefore be a useful
tool to optimize neuroreanimation activities based on mea-
sures of brain metabolites in extracellular fluid, excitotoxicity
and oxidative stress [40] in a the very early phase of SAH.
Equally PbtO2 monitoring could help in guiding therapeutic
decisions and in predicting the prognosis.
Pharmacological agents able to diminish EBImay include
vasodilators (calcium blockers, magnesium sulphate, ET-1
antagonists, NO donors, milrinone, and oestrogen therapy),
antioxidants, anti-inflammatory, or antiplatelet agents [13]
and iron binding molecules. A combination of these thera-
peutic options may be necessary to obtain a synergic effect.
New promising strategies include using pleiotropic
molecules with vasodilator properties (such as 17𝛽–estra-
diol), anti-inflammatory and antioxidative drugs, such as
astaxanthine or TNF𝛼 inhibitors, and molecules limiting mi-
crothrombus formation, such as ADAMTS-13.These showed
encouraging results in preclinical studies and it is now evident
that focusing on vasospasm treatment alone cannot achieve
improvement in functional outcome. Promoting strategies
to treat early brain injury will prevent many of the tragic
consequences of SAH and new therapeutic options should
concentrate further research into EBI and consequently DBI
determinants [88].
6. Conclusions
Delayed ischemic injury is a complex process, resulting from
the contribution of different pathological pathways and it
is the leading determinant of poor functional outcome in
patients surviving the initial hemorrhagic insult of aSAH.The
role of vasospasm has long been overemphasized. Delayed
vasospasm is not a necessary prerequisite for DIND devel-
opment. Vasospasm alone should not be used to monitor
the efficacy of therapeutic interventions nor used as a prog-
nostic marker. Indeed, its reversal alone is inadequate as a
therapeutic target. Many other mechanisms may underlie
prognosis and a contemporary therapeutic approach reacting
to multiple pathological pathways evident in early brain
injury should be sought. Despite extensive research and
aggressive management of cerebral vasospasm (both medical
and endovascular), SAH prognosis remains poor. Invasive
neuromonitoring to detect pathological alterations occurring
in early brain injury may permit prevention of DIND; such
therapeutic interventions need to be undertaken within the
first hours after aSAH.
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